Alligator Bioscience AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.11.19	Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity - New Preclinical Data to be Presented at SITC 34th Annual Meeting (PR Newswire)
06.11.19	Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity - New Preclinical Data to be Presented at SITC 34th Annual Meeting (PR Newswire)
24.10.19	Alligator Bioscience AB Interim Report January-September 2019 (PR Newswire)
24.10.19	Alligator Bioscience AB Interim Report January-September 2019 (PR Newswire)
20.08.19	Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc. (PR Newswire)
20.08.19	Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc. (PR Newswire)
31.07.19	Alligator Bioscience Regains Global Rights From Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107) (PR Newswire)
31.07.19	Alligator Bioscience Regains Global Rights From Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107) (PR Newswire)
11.07.19	Alligator Bioscience AB (publ) Interim Report January-June 2019 (PR Newswire)
11.07.19	Alligator Bioscience AB (publ) Interim Report January-June 2019 (PR Newswire)
18.06.19	Alligator Bioscience Submits Clinical Trial Application for ATOR-1017 (PR Newswire)
18.06.19	Alligator Bioscience Submits Clinical Trial Application for ATOR-1017 (PR Newswire)
16.05.19	Alligator Bioscience to Present the ATOR-1015 Phase I Study Outline at ASCO (PR Newswire)
16.05.19	Alligator Bioscience to Present the ATOR-1015 Phase I Study Outline at ASCO (PR Newswire)
16.05.19	Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO (PR Newswire)
16.05.19	Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO (PR Newswire)
17.04.19	The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ) (PR Newswire)
17.04.19	The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ) (PR Newswire)
17.04.19	Alligator Bioscience AB (publ) Interim Report January-March 2019 (PR Newswire)
17.04.19	Alligator Bioscience AB (publ) Interim Report January-March 2019 (PR Newswire)
17.04.19	Citycon Oyj's Interim Report for 1 January - 31 March 2019: Stable Overall Development Continued (PR Newswire)
10.04.19	Notice of Annual Shareholders' Meeting in Alligator Bioscience AB (publ) (PR Newswire)
10.04.19	Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston (PR Newswire)
10.04.19	Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston (PR Newswire)
02.04.19	Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects (PR Newswire)
02.04.19	Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects (PR Newswire)
22.03.19	Alligator Bioscience's Annual Report 2018 Published (PR Newswire)
22.03.19	Alligator Bioscience's Annual Report 2018 Published (PR Newswire)
18.03.19	Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017 (PR Newswire)
18.03.19	Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017 (PR Newswire)
07.03.19	Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015 (PR Newswire)
07.03.19	Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015 (PR Newswire)
14.02.19	Alligator Bioscience AB Year-end Report 2018 (PR Newswire)
14.02.19	Alligator Bioscience AB Year-end Report 2018 (PR Newswire)
12.02.19	Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update (PR Newswire)
12.02.19	Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update (PR Newswire)
29.01.19	Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer (PR Newswire)
29.01.19	Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer (PR Newswire)
07.01.19	Alligator Bioscience Launches RUBY™, a Novel Concept in Bispecific Antibody Formats (PR Newswire)
11.12.18	Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015 (PR Newswire)
11.12.18	Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015 (PR Newswire)
10.12.18	Frontier - A Magazine about Alligator Bioscience and Immuno-oncology (PR Newswire)
10.12.18	Frontier - A Magazine about Alligator Bioscience and Immuno-oncology (PR Newswire)
09.11.18	Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting (PR Newswire)
09.11.18	Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting (PR Newswire)
07.11.18	Alligator Bioscience to Receive Million-dollar Payments - AbClon Partner Exercises Option (PR Newswire)
07.11.18	Alligator Bioscience to Receive Million-dollar Payments - AbClon Partner Exercises Option (PR Newswire)
30.10.18	Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144 (PR Newswire)
30.10.18	Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144 (PR Newswire)
26.10.18	Alligator Bioscience AB Interim Report January-September 2018 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Alligator Bioscience AB

Aktien Top/Flop

Meistgelesene Nachrichten